{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:38:28Z","timestamp":1794440308377,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["2013025"],"award-info":[{"award-number":["2013025"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1160000"],"award-info":[{"award-number":["APP1160000"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009010"],"award-info":[{"award-number":["APP2009010"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AG059244"],"award-info":[{"award-number":["AG059244"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) increases with advancing age, suggesting that progression may be influenced by age-related changes within the bone marrow (BM) microenvironment. We hypothesise that senescent mesenchymal stromal cells (MSCs), which accumulate in the BM with age, may contribute to MGUS progression to MM. Here, we show that, like BM MSCs from aged non-cancer controls, BM MSCs from both MM and MGUS patients exhibit a senescent phenotype characterised by enlarged, flattened morphology, increased \u03b2-galactosidase activity and\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    expression, and decreased proliferation rate compared with BM MSCs from healthy young individuals. While coculture with BM MSCs suppresses the proliferative capacity of MM cell lines in vitro, induction of senescence via irradiation or replicative exhaustion in healthy MSCs relieves this suppression, compared with non-senescent MSCs. This may, in part, be attributable to upregulated expression of the BMP antagonist Gremlin1 in senescent MSCs, which facillitates MM cell proliferation. Notably, the risk of progression to MM was significantly elevated in MGUS patients with increased MSC senescence. Collectively, our data provide evidence that age-related accumulation of senescent MSCs may be a driver of MGUS to MM progression.\n                  <\/jats:p>","DOI":"10.1038\/s41375-025-02621-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T14:44:28Z","timestamp":1745333068000},"page":"1464-1475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma"],"prefix":"10.1038","volume":"39","author":[{"given":"Natalya","family":"Plakhova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa D.","family":"Cantley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-3963","authenticated-orcid":false,"given":"Laura J.","family":"Trainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan R.","family":"Hewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6277-8297","authenticated-orcid":false,"given":"Kimberley C.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-2413","authenticated-orcid":false,"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Cakouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Gronthos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-6167","authenticated-orcid":false,"given":"Andrew C. W.","family":"Zannettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof M.","family":"Mrozik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-849X","authenticated-orcid":false,"given":"Kate","family":"Vandyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2621_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:606.","journal-title":"BMC Cancer"},{"key":"2621_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/leu.2009.134","volume":"23","author":"O Landgren","year":"2009","unstructured":"Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691\u201397.","journal-title":"Leukemia"},{"key":"2621_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241\u20139.","journal-title":"N Engl J Med"},{"key":"2621_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","volume":"20","author":"C Cesana","year":"2002","unstructured":"Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625\u201334.","journal-title":"J Clin Oncol"},{"key":"2621_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.25999","volume":"96","author":"C Gran","year":"2021","unstructured":"Gran C, Liwing J, Wagner AK, Verhoek A, Gezin A, Alici E, et al. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. Am J Hematol. 2021;96:23\u201330.","journal-title":"Am J Hematol"},{"key":"2621_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.645593","volume":"9","author":"R Kumari","year":"2021","unstructured":"Kumari R, Jat P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Front Cell Dev Biol. 2021;9:645593.","journal-title":"Front Cell Dev Biol"},{"key":"2621_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41568-019-0156-2","volume":"19","author":"DV Faget","year":"2019","unstructured":"Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019;19:439\u201353.","journal-title":"Nat Rev Cancer"},{"key":"2621_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10555-022-10069-9","volume":"42","author":"N Plakhova","year":"2023","unstructured":"Plakhova N, Panagopoulos V, Vandyke K, Zannettino ACW, Mrozik KM. Mesenchymal stromal cell senescence in haematological malignancies. Cancer Metastasis Rev. 2023;42:277\u201396.","journal-title":"Cancer Metastasis Rev"},{"key":"2621_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.38","volume":"2","author":"JE Noll","year":"2012","unstructured":"Noll JE, Williams SA, Purton LE, Zannettino AC. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?. Blood Cancer J. 2012;2:e91.","journal-title":"Blood Cancer J"},{"key":"2621_CR10","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","volume":"82","author":"H Uchiyama","year":"1993","unstructured":"Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712\u201320.","journal-title":"Blood"},{"key":"2621_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","volume":"21","author":"J Corre","year":"2007","unstructured":"Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007;21:1079\u201388.","journal-title":"Leukemia"},{"key":"2621_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15669","volume":"184","author":"SJ Mehdi","year":"2019","unstructured":"Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, et al. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2019;184:578\u201393.","journal-title":"Br J Haematol"},{"key":"2621_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0545-6","volume":"9","author":"J Guo","year":"2018","unstructured":"Guo J, Zhao Y, Fei C, Zhao S, Zheng Q, Su J, et al. Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death Dis. 2018;9:512.","journal-title":"Cell Death Dis"},{"key":"2621_CR14","doi-asserted-by":"publisher","first-page":"e59756","DOI":"10.1371\/journal.pone.0059756","volume":"8","author":"T Andre","year":"2013","unstructured":"Andre T, Meuleman N, Stamatopoulos B, De Bruyn C, Pieters K, Bron D, et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One. 2013;8:e59756.","journal-title":"PLoS One"},{"key":"2621_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12819","volume":"53","author":"H Choi","year":"2020","unstructured":"Choi H, Kim Y, Kang D, Kwon A, Kim J, Min Kim J, et al. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma. Cell Prolif. 2020;53:e12819.","journal-title":"Cell Prolif"},{"key":"2621_CR16","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/leu.2012.126","volume":"26","author":"S Xu","year":"2012","unstructured":"Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, et al. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia. 2012;26:2546\u201349.","journal-title":"Leukemia"},{"key":"2621_CR17","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1080\/10428190701593644","volume":"48","author":"L Garderet","year":"2007","unstructured":"Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma. 2007;48:2032\u201341.","journal-title":"Leuk Lymphoma"},{"key":"2621_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1078-3","volume":"15","author":"R Berenstein","year":"2015","unstructured":"Berenstein R, Blau O, Nogai A, Waechter M, Slonova E, Schmidt-Hieber M, et al. Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region. BMC Cancer. 2015;15:68.","journal-title":"BMC Cancer"},{"key":"2621_CR19","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","volume":"111","author":"S Fitter","year":"2008","unstructured":"Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008;111:2538\u201347.","journal-title":"Blood"},{"key":"2621_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s00223-020-00796-y","volume":"108","author":"CJM Stapledon","year":"2021","unstructured":"Stapledon CJM, Stamenkov R, Cappai R, Clark JM, Bourke A, Bogdan Solomon L, et al. Relationships between the bone expression of Alzheimer\u2019s disease-related genes, bone remodelling genes and cortical bone structure in neck of femur fracture. Calcif Tissue Int. 2021;108:610\u201321.","journal-title":"Calcif Tissue Int"},{"key":"2621_CR21","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1172\/JCI20427","volume":"114","author":"M Miura","year":"2004","unstructured":"Miura M, Chen XD, Allen MR, Bi Y, Gronthos S, Seo BM, et al. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest. 2004;114:1704\u201313.","journal-title":"J Clin Invest"},{"key":"2621_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315\u201317.","journal-title":"Cytotherapy"},{"key":"2621_CR23","doi-asserted-by":"crossref","unstructured":"Clark KC, Hewett DR, Panagopoulos V, Plakhova N, Opperman KS, Bradey AL, et al. Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers (Basel). 2020;12:2149.","DOI":"10.3390\/cancers12082149"},{"key":"2621_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-015-0209-2","volume":"8","author":"JE Noll","year":"2015","unstructured":"Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, et al. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol. 2015;8:106","journal-title":"J Hematol Oncol"},{"key":"2621_CR25","unstructured":"Quach H, Prince HM, Harrison S, MSAG. Clinical Practice Guideline: Multiple Myeloma; 2022 01\/06\/2022."},{"key":"2621_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812\u201317.","journal-title":"Blood"},{"key":"2621_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","volume":"123","author":"I Turesson","year":"2014","unstructured":"Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338\u201345.","journal-title":"Blood"},{"key":"2621_CR28","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41375-018-0030-3","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32:1811\u201315.","journal-title":"Leukemia"},{"key":"2621_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"M Fane","year":"2020","unstructured":"Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20:89\u2013106.","journal-title":"Nat Rev Cancer"},{"key":"2621_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15728","volume":"8","author":"M Takasugi","year":"2017","unstructured":"Takasugi M, Okada R, Takahashi A, Virya Chen D, Watanabe S, Hara E. Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. Nat Commun. 2017;8:15729.","journal-title":"Nat Commun"},{"key":"2621_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.celrep.2015.12.016","volume":"14","author":"X Luo","year":"2016","unstructured":"Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, et al. Stromal-initiated changes in the bone promote metastatic niche development. Cell Rep. 2016;14:82\u201392.","journal-title":"Cell Rep"},{"key":"2621_CR32","doi-asserted-by":"publisher","first-page":"12072","DOI":"10.1073\/pnas.211053698","volume":"98","author":"A Krtolica","year":"2001","unstructured":"Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA. 2001;98:12072\u201377.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2621_CR33","doi-asserted-by":"publisher","first-page":"e113572","DOI":"10.1371\/journal.pone.0113572","volume":"9","author":"GH Di","year":"2014","unstructured":"Di GH, Liu Y, Lu Y, Liu J, Wu C, Duan HF. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS One. 2014;9:e113572.","journal-title":"PLoS One"},{"key":"2621_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ncb3195","volume":"17","author":"RM Laberge","year":"2015","unstructured":"Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17:1049\u201361.","journal-title":"Nat Cell Biol"},{"key":"2621_CR35","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1158\/0008-5472.CAN-06-3452","volume":"67","author":"D Liu","year":"2007","unstructured":"Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 2007;67:3117\u201326.","journal-title":"Cancer Res"},{"key":"2621_CR36","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1158\/0008-5472.CAN-05-1716","volume":"66","author":"C Bavik","year":"2006","unstructured":"Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006;66:794\u2013802.","journal-title":"Cancer Res"},{"key":"2621_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13578-015-0012-3","volume":"5","author":"Y Li","year":"2015","unstructured":"Li Y, Xu X, Wang L, Liu G, Li Y, Wu X, et al. Senescent mesenchymal stem cells promote colorectal cancer cells growth via galectin-3 expression. Cell Biosci. 2015;5:21.","journal-title":"Cell Biosci"},{"key":"2621_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2018-04-845420","volume":"133","author":"AM Abdul-Aziz","year":"2019","unstructured":"Abdul-Aziz AM, Sun Y, Hellmich C, Marlein CR, Mistry J, Forde E, et al. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment. Blood. 2019;133:446\u201356.","journal-title":"Blood"},{"key":"2621_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/rheumatology\/kel267","volume":"46","author":"C Bocelli-Tyndall","year":"2007","unstructured":"Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatol (Oxf). 2007;46:403\u201308.","journal-title":"Rheumatol (Oxf)"},{"key":"2621_CR40","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/sj.leu.2402924","volume":"17","author":"Y Nefedova","year":"2003","unstructured":"Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17:1175\u201382.","journal-title":"Leukemia"},{"key":"2621_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mc.22378","volume":"55","author":"O Attar-Schneider","year":"2016","unstructured":"Attar-Schneider O, Zismanov V, Dabbah M, Tartakover-Matalon S, Drucker L, Lishner M. Multiple myeloma and bone marrow mesenchymal stem cells\u2019 crosstalk: Effect on translation initiation. Mol Carcinog. 2016;55:1343\u201354.","journal-title":"Mol Carcinog"},{"key":"2621_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584683","volume":"10","author":"H Fairfield","year":"2020","unstructured":"Fairfield H, Costa S, Falank C, Farrell M, Murphy CS, D\u2019Amico A, et al. Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2020;10:584683.","journal-title":"Front Oncol"},{"key":"2621_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2023.101674","volume":"18","author":"RM Samsonraj","year":"2023","unstructured":"Samsonraj RM, Law SF, Chandra A, Pignolo RJ. An unbiased proteomics approach to identify the senescence-associated secretory phenotype of human bone marrow-derived mesenchymal stem cells. Bone Rep. 2023;18:101674.","journal-title":"Bone Rep"},{"key":"2621_CR44","doi-asserted-by":"publisher","first-page":"e3000599","DOI":"10.1371\/journal.pbio.3000599","volume":"18","author":"N Basisty","year":"2020","unstructured":"Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 2020;18:e3000599","journal-title":"PLoS Biol"},{"key":"2621_CR45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1097-2765(00)80067-2","volume":"1","author":"DR Hsu","year":"1998","unstructured":"Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell. 1998;1:673\u201383.","journal-title":"Mol Cell"},{"key":"2621_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cell.2014.11.042","volume":"160","author":"DL Worthley","year":"2015","unstructured":"Worthley DL, Churchill M, Compton JT, Tailor Y, Rao M, Si Y, et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell. 2015;160:269\u201384.","journal-title":"Cell"},{"key":"2621_CR47","doi-asserted-by":"publisher","first-page":"e0174884","DOI":"10.1371\/journal.pone.0174884","volume":"12","author":"A Seher","year":"2017","unstructured":"Seher A, Lagler C, Stuhmer T, Muller-Richter UDA, Kubler AC, Sebald W, et al. Utilizing BMP-2 muteins for treatment of multiple myeloma. PLoS One. 2017;12:e0174884.","journal-title":"PLoS One"},{"key":"2621_CR48","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/leu.2011.263","volume":"26","author":"T Holien","year":"2012","unstructured":"Holien T, Vatsveen TK, Hella H, Rampa C, Brede G, Groseth LA, et al. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia. 2012;26:1073\u201380.","journal-title":"Leukemia"},{"key":"2621_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-015-0104-z","volume":"13","author":"OE Olsen","year":"2015","unstructured":"Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, et al. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun Signal. 2015;13:27.","journal-title":"Cell Commun Signal"},{"key":"2621_CR50","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.V97.2.516","volume":"97","author":"O Hjertner","year":"2001","unstructured":"Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood. 2001;97:516\u201322.","journal-title":"Blood"},{"key":"2621_CR51","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1182\/blood.V96.6.2005","volume":"96","author":"C Kawamura","year":"2000","unstructured":"Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood. 2000;96:2005\u201311.","journal-title":"Blood"},{"key":"2621_CR52","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1038\/sj.onc.1207386","volume":"23","author":"TB Ro","year":"2004","unstructured":"Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 2004;23:3024\u201332.","journal-title":"Oncogene"},{"key":"2621_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115455","volume":"137","author":"GM Todd","year":"2020","unstructured":"Todd GM, Gao Z, Hyvonen M, Brazil DP, Ten Dijke P. Secreted BMP antagonists and their role in cancer and bone metastases. Bone. 2020;137:115455.","journal-title":"Bone"},{"key":"2621_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-198","volume":"10","author":"K Mahtouk","year":"2010","unstructured":"Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, Jourdan M, et al. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer. 2010;10:198.","journal-title":"BMC Cancer"},{"key":"2621_CR55","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1","volume":"91","author":"SR Wallace","year":"2001","unstructured":"Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer. 2001;91:1219\u201330.","journal-title":"Cancer"},{"key":"2621_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.leu.2404466","volume":"21","author":"B Arnulf","year":"2007","unstructured":"Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2007;21:158\u201363.","journal-title":"Leukemia"},{"key":"2621_CR57","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","volume":"73","author":"B Klein","year":"1989","unstructured":"Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517\u201326.","journal-title":"Blood"},{"key":"2621_CR58","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood.V88.6.2219.bloodjournal8862219","volume":"88","author":"M Urashima","year":"1996","unstructured":"Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G, Hoshi Y, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood. 1996;88:2219\u201327.","journal-title":"Blood"},{"key":"2621_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.V74.1.11.11","volume":"74","author":"XG Zhang","year":"1989","unstructured":"Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 1989;74:11\u20133.","journal-title":"Blood"},{"key":"2621_CR60","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/0145-2126(92)90073-G","volume":"16","author":"BA Barut","year":"1992","unstructured":"Barut BA, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohrbacher A, et al. Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk Res. 1992;16:951\u201359.","journal-title":"Leuk Res"},{"key":"2621_CR61","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","volume":"15","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009;15:7144\u201352.","journal-title":"Clin Cancer Res"},{"key":"2621_CR62","doi-asserted-by":"publisher","first-page":"13285","DOI":"10.18632\/oncotarget.7690","volume":"7","author":"K O\u2019Hagan-Wong","year":"2016","unstructured":"O\u2019Hagan-Wong K, Nadeau S, Carrier-Leclerc A, Apablaza F, Hamdy R, Shum-Tim D, et al. Increased IL-6 secretion by aged human mesenchymal stromal cells disrupts hematopoietic stem and progenitor cells\u2019 homeostasis. Oncotarget. 2016;7:13285\u201396.","journal-title":"Oncotarget"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02621-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02621-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:02:55Z","timestamp":1749099775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02621-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2621"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02621-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}